Noeul Unveils MyLab at Medlab 2025 in Dubai: Accelerating Emerging Market Expansion

Korean company Noul is accelerating its push into the Middle East and Asian markets by showcasing its artificial intelligence (AI)-based blood and cancer diagnostic solution, 'miLab™,' at '2025 Medlab Middle East,' the world's largest diagnostics and medical device exhibition held in Dubai. This international exhibition, running from February 3rd to 6th, is a prestigious event bringing together over 800 companies from more than 180 countries and attracting over 30,000 visitors. Through this exhibition, Noul has firmly established its innovative AI diagnostic technology on the global stage. Lim Chan-yang, CEO of Noul, stated his ambition to actively promote miLab's key product lines and seek strategic partnerships at the exhibition, adding, "We have completed preparations for entry into the Middle East market, including obtaining Class III AI medical device marketing approval in Saudi Arabia." From the very first day of the exhibition, Noul's booth saw visits from approximately 100 customers and partners, with over 40 active inquiries and meetings regarding potential partnerships. Notably, customers from major Middle Eastern countries such as Saudi Arabia, the UAE, and Kuwait, as well as those from Asia and Africa, showed significant interest in Noul's AI-based blood analysis and cervical cytology solutions. Noul introduced three main products at this exhibition. These include 'miLab™ BCM,' an innovative AI-based blood analysis solution poised to replace peripheral blood smear tests, which are performed over 680 million times annually worldwide; 'miLab™ CER,' an AI-based cervical cytopathology test recommended for use in the 2024 World Health Organization (WHO)-UNITAID report; and 'miLab™ MAL,' a malaria point-of-care diagnostic technology recognized for its excellence by the international community. Noul has already secured medical device marketing approvals in Saudi Arabia, the largest market in the Middle East, for its malaria diagnostic auxiliary software and cartridges (Class III) and its blood analysis auxiliary software and cartridges (Class I), thereby laying the groundwork for global market expansion.